FROM THE EDITORS
Welcome to the HR+ HER2- Breast Cancer Resource Center! We’re excited to present you with current information, news items, highlights from the literature, and other resources that focus on this disease space and the advanced practitioner’s role in delivering high-quality care to patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.
![]() |
![]() |
Katie Newlin, RN, MSN, AGPCNP-BC Washington University in St. Louis/Siteman Cancer Center
|
Kate Taucher, PharmD, MHA, BCOP, FASHP, FAPO, FHOPA UCHealth Memorial Hospital |
Resources
Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update
Ribociclib Plus Endocrine Therapy in Early Breast Cancer
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)
Oral Chemotherapy Education
Clinical Characteristics and Treatment Persistence in US Patients with HR+/HER2-, Node Positive Early Breast Cancer Treated with Abemaciclib: Real-World Study from First Year After Approval
News & Literature Highlights